XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 6 Months Ended
Aug. 31, 2024
Jun. 30, 2023
Aug. 02, 2024
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
Change in Accounting Estimate [Line Items]            
Letter of credit established as a deposit       $ 1,500    
Cash and cash equivalents   $ 66,830   $ 27,786 $ 45,204 $ 100,444
Forecast            
Change in Accounting Estimate [Line Items]            
Contract With Customer, Expected Consideration To Be Received $ 50,000          
Genentech, Roche Group | License | Forecast            
Change in Accounting Estimate [Line Items]            
Deferred revenues $ 40,000          
Genentech, Roche Group | Subsequent Event | License            
Change in Accounting Estimate [Line Items]            
Deferred revenues     $ 40,000      
Variable consideration amount     $ 10,000      
Kite Pharma, Inc.            
Change in Accounting Estimate [Line Items]            
Increase in revenue   8,900        
Increase in net income   $ 8,900        
Increased earnings per share, basic (in dollars per share)   $ 0.06        
Increased earnings per share, diluted (in dollars per share)   $ 0.06